Drug susceptibility of reference species of rapidly growing mycobacteria against 10 new antimicrobial agents
PANG Hui1, 2, 3, LI Gui-lian3, 4, WAN Kang-lin3, 4, YU Ping1
1.Department of Immunology, Xiangya School of Medicine, Central South University, Changsha 410078, China; 2.Department of Immunology, Changzhi Medical College, Changzhi 046000, China; 3.State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; 4.Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310000, China
Abstract:An increasing number of rapidly growing mycobacteria (RGM) are being found to be resistant to conventional antituberculous agents and have been associated with a broad spectrum of diseases. In this study, a cation-adjusted Mueller-Hinton broth microdilution assay was employed to assess the susceptibility of 40 reference species of RGM to 10 new antimicrobial agents. Clofazimine (39/40) was found to be the most effective antimicrobial agent tested against the RGM species, closely followed by sparfloxacin (37/40) and cefmetazole (36/40). Roxithromycin (33/40), azithromycin (31/40) and rifapentine (29/40) displayed a good level of activity, and rifabutin (16/40) showed moderate activity. Dapsone (4/40) and pasiniazid (9/40) displayed little antimicrobial activity against RGM species, and thioacetazone (1/40) was the least effective agent. Among the 40 reference RGM species, Mycobacterium aurum, Mycobacterium duvalii and Mycobacterium parafortuitum exhibited 80% susceptibility to the tested drugs, and Mycobacterium massiliense, Mycobacterium boenickei and Mycobacterium porcinum exhibited 30% susceptibility to these agents. All other species displayed 40-70% susceptibility. These data will be valuable for physicians when formulating and optimizing drug treatment programs for RGM.
庞慧, 李桂莲, 万康林, 余平. 快速生长分枝杆菌标准株对10种新型抗菌药物的敏感性[J]. 中国人兽共患病学报, 2015, 31(9): 783-788.
PANG Hui, LI Gui-lian, WAN Kang-lin, YU Ping. Drug susceptibility of reference species of rapidly growing mycobacteria against 10 new antimicrobial agents. Chinese Journal of Zoonoses, 2015, 31(9): 783-788.
[1] Huang TS, Lee SS, Hsueh PR, et al. Antimicrobial resistance of rapidly growing mycobacteria in western Taiwan: SMART program 2002[J]. J Formos Med Assoc, 2008, 107(4): 281-287. [2] Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontubercul ous mycobacterial diseases[J]. Am J Respir Crit Care Med, 2007, 175(4): 367-416. [3] Govendir M, Hansen T, Kimble B, et al. Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin andmoxifloxacin[J]. Vet Microbiol, 2011, 147(1-2): 113-118. doi:10.1016/j.vetmic.2010.06.011 [4] El Helou G, Viola GM, Hachem R, et al. Rapidly growing mycobacterial bloodstream infections[J]. Lancet Infect Dis, 2013, 13(2): 166-174. doi:10.1016/S1473-3099(12)70316-X [5] Clinical and Laboratory Standards Institute: Susceptibility Testing of Mycobacteria, Nocardiae, and Other aerobic actinomycetes; Approved Standard Second Edition[S]. CLSI document M24-A2, 2011. [6] World Health Organization: Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs[M]. Geneva: WHO, 2008. [7] Kłosinska-Szmurło E, Plucinski FA, Grudzien M, et al. Experimental and theoretical studies on the molecular properties of ciprofloxacin, norfloxacin, pefloxacin, sparfloxacin, and gatifloxacin in determining bioavailability[J]. J Biol Phys, 2014, 40(4): 335-345. [8] Gopal M, Padayatchi N, Metcalfe JZ, et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis[J]. Int J Tuberc Lung Dis, 2013, 17(8): 1001-1007. [9] Samra Z, Rosenberg S, Dan M. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin[J]. J Chemother, 2011, 23(2): 77-79. [10] Shen GH, Wu BD, Hu ST, et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria[J]. Int J Antimicrob Agents, 2010, 35(4): 400-404. [11] Coxon GD, Craig D, Corrales RM, et al. Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues[J]. PLoS One, 2013, 8(1): e53162. [12] Staudinger T, Redl B, Glasgow BJ. Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalin[J]. Biochim Biophys Acta, 2014, 1844 (4): 750-758. [13] Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; twenty first informational supplement[S]. CLSI document M100-S21, 2011. [14] Zhang Z, Lu J, Wang Y, et al. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China[J]. Antimicrob Agents Chemother, 2014, 58(1): 364-369. doi:10.1128/AAC.01228-13 [15] Shen GH, Wu BD, Hu ST, et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growingmycobacteria [J]. Int J Antimicrob Agents, 2010, 35 (4): 400-404. doi:10.1016/j.ijantimicag.2009.12.008 [16] van Ingen J, Totten SE, Helstrom NK, et al. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease[J]. Antimicrob Agents Chemother, 2012, 56 (12): 6324-6327. doi:10.1128/AAC.01505-12 [17] Saribas Z, Kocagoz T, Alp A, et al. Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heteroduplex analysis and determination of rifamycin cross-resistance in rifampin-resistant isolates[J]. J Clin Microbiol, 2003, 41(2): 816-818.